AXON:NYE-Axovant Sciences Ltd. (USD)

EQUITY | Aerospace & Defense | New York Stock Exchange

Last Closing

USD 300.01

Change

-4.71 (-1.55)%

Market Cap

USD 1.28B

Volume

0.66M

Analyst Target

USD 4.40
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Axovant Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of dementia.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-31 )

Largest Industry Peers for Aerospace & Defense

Symbol Name Price(Change) Market Cap
WWD Woodward Inc

N/A

USD 9.67B
ESLT Elbit Systems Ltd

N/A

USD 9.10B
AVAV AeroVironment Inc

N/A

USD 5.06B
KTOS Kratos Defense & Security Solu..

N/A

USD 3.33B
RKLB Rocket Lab USA Inc.

N/A

USD 3.11B
MRCY Mercury Systems Inc

N/A

USD 2.23B
VSEC VSE Corporation

N/A

USD 1.59B
EH Ehang Holdings Ltd

N/A

USD 0.76B
ATRO Astronics Corporation

N/A

USD 0.72B
SWBI Smith & Wesson Brands Inc

N/A

USD 0.66B

ETFs Containing AXON

XAR SPDR® S&P Aerospace & De.. 5.21 % 0.35 %

N/A

USD 2.34B
XAD:CA iShares U.S. Aerospace & .. 4.42 % 0.00 %

N/A

N/A
DFEN Direxion Daily Aerospace .. 2.95 % 1.09 %

N/A

USD 0.18B
MMSC First Trust Multi-Manager.. 1.96 % 0.00 %

N/A

USD 0.02B
EQJS:LSE Invesco NASDAQ Next Gener.. 1.87 % 0.00 %

N/A

USD 0.04B
TMFX Motley Fool Next Index ET.. 1.65 % 0.00 %

N/A

USD 0.02B
EQQJ:XETRA Invesco NASDAQ Next Gener.. 1.57 % 0.00 %

N/A

USD 0.05B
EQQJ:LSE Invesco NASDAQ Next Gener.. 1.55 % 0.00 %

N/A

N/A
RSPN Invesco S&P 500® Equal.. 1.47 % 0.00 %

N/A

USD 0.71B
IQCT:LSE Amundi Index Solutions - .. 1.43 % 0.00 %

N/A

USD 0.08B
QWST 1.36 % 0.00 %

N/A

N/A
IQCY:LSE Amundi Index Solutions - .. 1.25 % 0.00 %

N/A

N/A
SCITY:PA 1.20 % 0.00 %

N/A

N/A
SCITY:SW Amundi Index Solutions - .. 1.20 % 0.00 %

N/A

USD 0.08B
TRFM ETF Series Solutions - AA.. 0.93 % 0.00 %

N/A

USD 0.04B
VBK Vanguard Small-Cap Growth.. 0.84 % 0.07 %

N/A

USD 17.64B
JPSC:XETRA JPMorgan BetaBuilders US .. 0.41 % 0.00 %

N/A

N/A
CHEP 0.00 % 1.12 %

N/A

N/A
ITA 0.00 % 0.42 %

N/A

N/A
SCHM Schwab U.S. Mid-Cap ETF 0.00 % 0.05 %

N/A

N/A
VB Vanguard Small-Cap Index .. 0.00 % 0.05 %

N/A

N/A
BFTR 0.00 % 0.00 %

N/A

N/A
JOET Virtus ETF Trust II 0.00 % 0.00 %

N/A

USD 0.12B
QQQJ Invesco NASDAQ Next Gen 1.. 0.00 % 0.00 %

N/A

USD 0.65B
QQQN VictoryShares Nasdaq Next.. 0.00 % 0.00 %

N/A

USD 0.03B
AMEC:XETRA Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

USD 9.60M

Market Performance

  Market Performance vs. Industry/Classification (Aerospace & Defense) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.13% 69% C- 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.13% 69% C- 76% C+
Trailing 12 Months  
Capital Gain 68.53% 85% B 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 68.53% 85% B 92% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 20.31% 75% C 79% B-
Dividend Return 20.31% 75% C 78% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 40.28% 58% F 44% F
Risk Adjusted Return 50.43% 81% B- 79% B-
Market Capitalization 1.28B 100% F 96% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Aerospace & Defense) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 88.58 10% 11%
Price/Book Ratio 14.55 8% 8%
Price / Cash Flow Ratio 121.50 7% 2%
Price/Free Cash Flow Ratio 117.35 4% 2%
Management Effectiveness  
Return on Equity 16.29% 93% 86%
Return on Invested Capital 8.22% 82% 74%
Return on Assets 2.96% 80% 78%
Debt to Equity Ratio 42.00% 22% 45%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.